ranolazine has been researched along with Cardiac Diseases in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Bernardini, F; Grigioni, F; Maddaloni, E; Manfrini, S; Mangiacapra, F; Melfi, R; Nusca, A; Piccirillo, F; Ricottini, E; Ussia, GP | 1 |
| Corradi, F; De Caterina, R; Paolini, L | 2 |
| Minotti, G | 1 |
| Ahmad, A; Ahmad, S; Chandler, JD; Claycomb, WC; Day, BJ; Hendry-Hofer, TB; Loader, JE; Mozziconacci, O; Powell, RL; Reisdorph, N; Schöneich, C; Veress, LA; White, CW | 1 |
| Reddy, BM; Schwartzbard, AZ; Weintraub, HS | 1 |
| Zaza, A | 1 |
| Maier, LS; Sossalla, S | 1 |
6 review(s) available for ranolazine and Cardiac Diseases
| Article | Year |
|---|---|
[Ranolazine in the prevention of anthracycline-related cardiotoxicity].
Topics: Acetanilides; Anthracyclines; Enzyme Inhibitors; Heart Diseases; Humans; Piperazines; Ranolazine | 2013 |
Pharmacology at work for cardio-oncology: ranolazine to treat early cardiotoxicity induced by antitumor drugs.
Topics: Acetanilides; Adolescent; Adult; Aged; Antineoplastic Agents; Enzyme Inhibitors; Female; Heart Diseases; Heart Failure, Diastolic; Humans; Male; Middle Aged; Multicenter Studies as Topic; Piperazines; Randomized Controlled Trials as Topic; Ranolazine; Risk Assessment; Young Adult | 2013 |
Ranolazine in the prevention of anthracycline cardiotoxicity.
Topics: Acetanilides; Animals; Anthracyclines; Antibiotics, Antineoplastic; Cardiotonic Agents; Heart Diseases; Humans; Piperazines; Ranolazine; Sodium Channel Blockers | 2014 |
Ranolazine: a new approach to treating an old problem.
Topics: Acetanilides; Angina Pectoris; Angina, Unstable; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Evidence-Based Medicine; Heart Diseases; Heart Failure, Diastolic; Humans; Myocardial Infarction; Piperazines; Practice Guidelines as Topic; Ranolazine; Sodium Channel Blockers; Treatment Outcome | 2010 |
[The late sodium current: pathophysiology and pharmacology of a new therapeutic target].
Topics: Acetanilides; Arrhythmias, Cardiac; Disease Progression; Enzyme Inhibitors; Heart Conduction System; Heart Diseases; Humans; Muscle Cells; Myocardial Contraction; Myocardial Ischemia; Piperazines; Ranolazine; Sodium; Sodium Channels; Treatment Outcome | 2011 |
Role of ranolazine in angina, heart failure, arrhythmias, and diabetes.
Topics: Acetanilides; Animals; Cardiovascular Agents; Diabetes Mellitus; Heart Diseases; Humans; Piperazines; Ranolazine | 2012 |
2 other study(ies) available for ranolazine and Cardiac Diseases
| Article | Year |
|---|---|
Ranolazine Improves Glycemic Variability and Endothelial Function in Patients with Diabetes and Chronic Coronary Syndromes: Results from an Experimental Study.
Topics: Analysis of Variance; Diabetes Mellitus; Endothelial Cells; Female; Glycemic Control; Heart Diseases; Humans; Male; Middle Aged; Prospective Studies; Ranolazine; Sodium Channel Blockers; Statistics, Nonparametric | 2021 |
Sarcoendoplasmic reticulum Ca(2+) ATPase. A critical target in chlorine inhalation-induced cardiotoxicity.
Topics: Adenosine Triphosphate; Animals; Antioxidants; Apoptosis; Calcium Signaling; Cardiotonic Agents; Cells, Cultured; Chlorine; Etiocholanolone; Heart Diseases; Inhalation Exposure; Male; Mitochondria, Heart; Myocardium; Myocytes, Cardiac; Ranolazine; Rats, Sprague-Dawley; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Thiocyanates | 2015 |